PDCD1 and maculopapular eruption: Notably, PD-1/PD-L1 antibodies are of lower risk of maculopapular rashes (MPR) compared to CTLA-4 antibodies (Bottlaender et al., 2020; Curry et al., 2017; Minkis et al., 2013).